Condition
Sclerotherapy
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (4)
Trial Status
Completed2
Recruiting2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07678697Not ApplicableRecruiting
Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique
NCT07481617Not Yet Recruiting
Laparoscopic Sclerotherapy for the Management of Ovarian Endometriomas
NCT05962775Not ApplicableRecruiting
Ethanol Sclerotherapy Prior to ART
NCT06274086Not ApplicableCompletedPrimary
Two-session Catheter-directed Sclerotherapy Using Ethanol for Endometrioma
NCT04132323Not ApplicableCompletedPrimary
Low Concentrate Detergents Versus Hypertonic Glucose for the Treatment of Telangiectasia
Showing all 5 trials